ArticleThe Lancet regional health. Europe2026

Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension.

Katharina A Mayer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.